IL17A and COVID-19: There were no significant differences in the rates of COVID-19 hospitalization between the patients with psoriasis receiving IL-17 inhibitors and those receiving non-biologics in the confirmed cases group (RR: 0.57; 95% CI: 0.21-1.52; P = 0.26) and in the suspected cases group (RR: 3.39; 95% CI: 0.73-15.73; P = 0.12), respectively (Figure 5B).